We are live on ! Find out more
ARQT icon

Arcutis Biotherapeutics

187 hedge funds and large institutions have $1.18B invested in Arcutis Biotherapeutics in 2024 Q2 according to their latest regulatory filings, with 48 funds opening new positions, 59 increasing their positions, 55 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

158% more call options, than puts

Call options by funds: $7.02M | Put options by funds: $2.72M

66% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 29

11% more funds holding

Funds holding: 168 → 187 (+19)

7% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 55

6% more capital inflows, than outflows

Capital inflows: $183M | Capital outflows: $173M

0.58% more ownership

Funds ownership: 108.71% → 109.29% (+0.58%)

33% less funds holding in top 10

Funds holding in top 10: 6 → 4 (-2)

Holders
187
Holders Change
+19
Holders Change %
+11.31%
% of All Funds
2.69%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.06%
New
48
Increased
59
Reduced
55
Closed
29
Calls
$7.02​M
Puts
$2.72​M
Net Calls
+$4.3​M
Net Calls Change
+$8.98​M

ARQT Hedge Fund Activity: Q2 2024 in Review

187 of the 6,946 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q2 2024, worth a combined $1.18B — down 5% from $1.24B a quarter earlier.

Buyers outnumbered sellers: 48 funds opened new ARQT positions and 29 closed out — a net gain of 19 holders — while 59 added to existing stakes and 55 trimmed.

The largest buyer was Rubric Capital Management (New York), adding an estimated $20.9M. The largest seller was State Street, cutting an estimated $33M.

  • 187 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q2 2024, up from 168 in Q1 2024.
  • Funds reported $1.18B of Arcutis Biotherapeutics stock for Q2 2024, down 5% quarter-over-quarter.
  • 48 funds opened new Arcutis Biotherapeutics positions in Q2 2024 and 29 closed out, a net change of +19 holders.
  • The largest Arcutis Biotherapeutics buyer in Q2 2024 was Rubric Capital Management (New York), an estimated $20.9M added.
  • The largest Arcutis Biotherapeutics seller in Q2 2024 was State Street, an estimated $33M sold.

Based on aggregated 13F filings for Q2 2024.